Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome

Conclusions The present propensity-matched analysis showed a significant association with survival for earlier delivery of chemotherapy in the adjuvant setting.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research

Related Links:

Conclusions: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine. PMID: 31533931 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Pancreatic adenocarcinoma is a high-mortality neoplasm with a documented 5-years-overall survival around 5%. In the last decades, a real breakthrough in the treatment of the disease has not been achieved. Here...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
Abstract More than eighty percent of pancreatic cancer involves ductal adenocarcinoma with an abundant desmoplastic extracellular matrix surrounding the solid tumor entity. This aberrant tumor microenvironment facilitates a strong resistance of pancreatic cancer to medication. Although various therapeutic strategies have been reported to be effective in mice with pancreatic cancer, they still need to be tested quantitatively in wider animal-based experiments before being applied as therapies. To aid the design of experiments, we develop a cell-based mathematical model to describe cancer progression under therapy w...
Source: Biomechanics and Modeling in Mechanobiology - Category: Biomedical Science Authors: Tags: Biomech Model Mechanobiol Source Type: research
Conclusion: Real-life data for Korean patients indicate that, consistent with NAPOLI-1, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with mPAC that progressed on gemcitabine-based therapy. PMID: 31489036 [PubMed]
Source: JOP - Category: Gastroenterology Authors: Tags: Ther Adv Med Oncol Source Type: research
as Löhr Clinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemcitabine alone (n = 185; 6.6 months (95% CI; 5.5–7.7)) was the same as in pivotal RCTs. Gemcitabine/capecitabine (n = 60; 10.6 months (95% CI; 7.8–13.3)) and gemcitabine/nab-paclitaxel (n = 66; 9.8 months (95% CI; 7.9–11.8)) resulted in a longer median OS and fluorouracil/oxaliplatin/...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractThe application of robotic technology allows for the performance of multi-organ liver resections by multidisciplinary teams in a minimally invasive manner. Their technique and outcomes are not established. Herein we describe our technique with robotic liver surgery combined with colon, pancreas and urologic resections. Our patients are an 84-year-old (yo) female (Body Mass Index, BMI: 25) with a recently diagnosed right colon adenocarcinoma and two synchronous liver metastases at segments 5 and 6, a 75-year-old female (BMI: 50.4) with a history of right renal cell cancer status post (s/p) right robotic radical neph...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide, associated with poor prognosis even when diagnosed at an early clinical stage (CS). Despite advances in surgery, radiotherapy, and chemotherapy, the 5-year overall survival rate is only 7.0-8.5% [1]. FOLFIRINOX (5-fluorouracil, irinotecan, and oxaliplatin) and nab-paclitaxel plus gemcitabine are first-line treatment options in the metastatic setting, with a median overall survival of less than 1 year [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research
This secondary analysis of a randomized clinical trial investigates patterns of recurrence after adjuvant chemotherapy in pancreatic cancer and the association with survival.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
ConclusionPost-PD NAFLD was associated with malnutrition in patients with PDAC, reducing their tolerance to gemcitabine-based adjuvant chemotherapy. Post-PD NAFLD needs to be emphasized and requires special nutritional intervention in patients with PDAC.
Source: Surgery Today - Category: Surgery Source Type: research
AbstractBackgroundStudies have demonstrated that multimodality therapy and surgery at high volume centers are associated with a longer survival. However, it is unknown if these data have translated into national changes in care delivery.MethodsPatients with stages I –III pancreatic adenocarcinomas who underwent resections between 2004 and 2010 were identified from the National Cancer Data Base. The primary outcome was a 3-year overall survival. Temporal trends in survival outcomes and treatment variables were measured. A mediation analysis using the Lin metho d was used to discern the relative contribution of changes...
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Gastroenterology | Insurance | Pancreas | Pancreatic Cancer